Related Experiment Video
Updated: Apr 25, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
[Antiplatelet drugs]
Insights
Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin prevents ischemic events but has limitations. Newer antiplatelet agents like prasugrel and ticagrelor offer alternatives for patients with suboptimal clopidogrel response.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Antiplatelet therapy, including dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, is crucial for preventing ischemic complications in patients with coronary heart disease and stroke.
- Current guidelines recommend DAPT for acute coronary syndrome and percutaneous coronary intervention.
Purpose of the Study:
- To review the limitations of clopidogrel-based DAPT, such as variable patient response and delayed platelet recovery.
- To discuss the pharmacologic properties and clinical evidence for newer antiplatelet agents.
Main Methods:
- Literature review of pharmacologic properties and clinical studies.
- Focus on new antiplatelet drugs: prasugrel, ticagrelor, and PAR-1 inhibitors.
Main Results:
- Clopidogrel therapy can exhibit low response rates, detected by platelet reactivity or genetic testing.
- Patients may experience a slower return to normal platelet activity after clopidogrel use, impacting surgical procedures.
- Newer agents present alternative therapeutic options.
Conclusions:
- Limitations of clopidogrel necessitate exploration of alternative antiplatelet strategies.
- Prasugrel, ticagrelor, and PAR-1 inhibitors represent advancements in antiplatelet therapy for cardiovascular disease prevention.
Abstract:
Antiplatelet therapy is widely used with proven benefit for the prevention of further ischemic complications in patients with coronary heart disease and stroke. Treatment guidelines for acute coronary syndrome and percutaneous coronary intervention now recommend the use of oral antiplatelet agents including clopidogrel in combination with aspirin (dual antiplatelet therapy: DAPT) for the prevention of recurrent ischemic events. The limitations of DAPT with clopidogrel include the potential for low response to clopidogrel identified through platelet reactivity or genetic testing, or slower return to normal platelet activity in patients who received clopidogrel prior to emergent or planned surgical procedures. This review will discuss the pharmacologic properties and clinical studies about new antiplatelet drugs including prasugrel, ticagrelor and PAR-1 inhibitors.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Peripheral Artery Disease III: Interprofessional Care
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

